» Articles » PMID: 23550968

Review and Assessment of Poliovirus Immunity and Transmission: Synthesis of Knowledge Gaps and Identification of Research Needs

Abstract

With the intensifying global efforts to eradicate wild polioviruses, policymakers face complex decisions related to achieving eradication and managing posteradication risks. These decisions and the expanding use of inactivated poliovirus vaccine (IPV) trigger renewed interest in poliovirus immunity, particularly the role of mucosal immunity in the transmission of polioviruses. Sustained high population immunity to poliovirus transmission represents a key prerequisite to eradication, but poliovirus immunity and transmission remain poorly understood despite decades of studies. In April 2010, the U.S. Centers for Disease Control and Prevention convened an international group of experts on poliovirus immunology and virology to review the literature relevant for modeling poliovirus transmission, develop a consensus about related uncertainties, and identify research needs. This article synthesizes the quantitative assessments and research needs identified during the process. Limitations in the evidence from oral poliovirus vaccine (OPV) challenge studies and other relevant data led to differences in expert assessments, indicating the need for additional data, particularly in several priority areas for research: (1) the ability of IPV-induced immunity to prevent or reduce excretion and affect transmission, (2) the impact of waning immunity on the probability and extent of poliovirus excretion, (3) the relationship between the concentration of poliovirus excreted and infectiousness to others in different settings, and (4) the relative role of fecal-oral versus oropharyngeal transmission. This assessment of current knowledge supports the immediate conduct of additional studies to address the gaps.

Citing Articles

Modeling the spread of circulating vaccine-derived poliovirus type 2 outbreaks and interventions: A case study of Nigeria.

Sun Y, Keskinocak P, Steimle L, Kovacs S, Wassilak S Vaccine X. 2024; 18:100476.

PMID: 38617838 PMC: 11011220. DOI: 10.1016/j.jvacx.2024.100476.


Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization.

Thompson K, Kalkowska D, Kidd S, Burns C, Badizadegan K Vaccine. 2024; 42(4):819-827.

PMID: 38218668 PMC: 10947589. DOI: 10.1016/j.vaccine.2023.12.081.


Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation.

Kalkowska D, Wassilak S, Wiesen E, Estivariz C, Burns C, Badizadegan K Gates Open Res. 2023; 7:55.

PMID: 37547300 PMC: 10403636. DOI: 10.12688/gatesopenres.14511.1.


The role of time-varying viral shedding in modelling environmental surveillance for public health: revisiting the 2013 poliovirus outbreak in Israel.

Brouwer A, Eisenberg M, Shulman L, Famulare M, Koopman J, Kroiss S J R Soc Interface. 2022; 19(190):20220006.

PMID: 35582812 PMC: 9114981. DOI: 10.1098/rsif.2022.0006.


One Full or Two Fractional Doses of Inactivated Poliovirus Vaccine for Catch-up Vaccination in Older Infants: A Randomized Clinical Trial in Bangladesh.

Aziz A, Verma H, Jeyaseelan V, Yunus M, Nowrin S, Moore D J Infect Dis. 2022; 226(8):1319-1326.

PMID: 35575051 PMC: 9574668. DOI: 10.1093/infdis/jiac205.


References
1.
Elmer F, Seifert I, Kreibich H, Thieken A . A delphi method expert survey to derive standards for flood damage data collection. Risk Anal. 2009; 30(1):107-24. DOI: 10.1111/j.1539-6924.2009.01325.x. View

2.
Sutter R, John T, Jain H, Agarkhedkar S, Venkat Ramanan P, Verma H . Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet. 2010; 376(9753):1682-8. DOI: 10.1016/S0140-6736(10)61230-5. View

3.
Oostvogel P, van Wijngaarden J, van der Avoort H, Mulders M, Conyn-Van Spaendonck M, Rumke H . Poliomyelitis outbreak in an unvaccinated community in The Netherlands, 1992-93. Lancet. 1994; 344(8923):665-70. DOI: 10.1016/s0140-6736(94)92091-5. View

4.
Chumakov K, Ehrenfeld E, Wimmer E, Agol V . Vaccination against polio should not be stopped. Nat Rev Microbiol. 2007; 5(12):952-8. DOI: 10.1038/nrmicro1769. View

5.
Thompson K, Tebbens R, Pallansch M, Kew O, Sutter R, Aylward R . Development and consideration of global policies for managing the future risks of poliovirus outbreaks: insights and lessons learned through modeling. Risk Anal. 2006; 26(6):1571-80. DOI: 10.1111/j.1539-6924.2006.00841.x. View